Adam E Logal's most recent trade in Opko Health Inc was a trade of 437,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 27, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Opko Health Inc | Adam E. Logal | Sr. Vice President, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2025 | 437,500 | 437,500 | - | - | Stock Option (Right to Buy) | |
| Opko Health Inc | Adam E. Logal | Sr. Vice President, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2024 | 437,500 | 616,662 (0%) | 0% | 0 | Common Stock | |
| Xenetic Biosciences Inc | Adam E. Logal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2023 | 2,500 | 2,500 | - | - | Stock Options | |
| Opko Health Inc | Adam E. Logal | Sr. Vice President, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 700,000 | 700,000 | - | - | Stock Option (Right to Buy) | |
| Xenetic Biosciences Inc | Adam E. Logal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2021 | 25,000 | 25,000 | - | - | Stock Options | |
| Opko Health Inc | Adam E. Logal | Sr. Vice President, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 350,000 | 350,000 | - | - | Stock Option (Right to Buy) |